Oricell Therapeutics
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $155M
Overview
A China-based biotech developing next-generation CAR-T cell therapies for oncology and immunology.
OncologyImmunology
Technology Platform
The OriCAR platform is a proprietary CAR-T technology designed to improve T-cell persistence, potency, and safety profiles.
Funding History
2Total raised:$155M
Pre-IPO$110M
Series B$45M
Opportunities
Significant market opportunity in China and globally for more effective and accessible cell therapies, especially for solid tumors.
Risk Factors
Faces intense competition, high manufacturing costs, and clinical risks associated with novel targets and next-gen engineering.
Competitive Landscape
Competes in the crowded CAR-T space with global leaders and numerous Chinese biotechs like JW Therapeutics and IASO Bio.